Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AusperBio Raises $37 Million in Series A Round for Antisense Oligonucleotides

publication date: Jul 18, 2024

AusperBio, a Hangzhou-San Francisco biotech, completed a $37 million Series A financing. The company develops therapies based on its novel oligonucleotide and targeted delivery technologies, focusing initially on curing chronic hepatitis B infection. Its lead drug is AHB-137, an unconjugated antisense oligonucleotide (ASO) developed by the company’s proprietary Med-Oligo™ ASO technology platform. In preclinical and Phase 1 clinical studies, the candidate has shown promise as an HVB cure, according to AusperBio. The A round was led by existing investor, InnoPinnacle Fund, with participation from new investors Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital and Genesis Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here